LOXO-195 - Selitrectinib

Based on 21 reference(s) in Google Scholar 10 12 21

Axon 3901

CAS [2097002-61-2]

MF C20H21FN6O
MW 380.42

  • Purity: 99%
  • Optical purity: 99%
  • Soluble in DMSO

LOXO-195

Description

LOXO-195 is an oral, second generation TRK inhibitor being made to address the acquired resistance to first generation TRK inhibitor (such as LOXO-101 (Axon 3407)). LOXO-195 potently and selectively inhibits, with minimal activity against other kinases, pan-TRKs (with potency on par with that of LOXO-101), and more importantly, abrogates resistance in TRK fusion–positive cancers that acquired kinase domain mutations due to the treatment of existing TRK inhibitors. Displays high oral bioavailability and favorable PK in animals.

KEYWORDS: LOXO-195 | Supplier | Trk inhibitor | Selitrectinib | LOXO195 | LOXO 195 | CT-LX195 | CAS [2097002-61-2] | Neurotrophin | Trk | inhibitor | Receptors

Trk inhibitor

Chemical name

(3aR,10R)-5-Fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-12H-15,17-Ethenopyrazolo[3,4-d]pyrido[2,3-k]pyrrolo[2,1-m][1,3,7]triazacyclotridecin-12-one,

Source information

Sold in collaboration with Chemietek

Parent CAS No.

[2097002-61-2]

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...